SGLT2 inhibitors are not currently advised in chronic kidney disease patients with an estimated glomerular filtration rate (eGFR) of <45mL/min/1.73m2 for empagliflozin and canagliflozin, and <60mL/min/1.73m2 for dapagliflozin [12,13,14]. Here, SLC5A2 is linked to chronic kidney disease.